开拓药业-B(09939)发布公告，防脱泡沫剂产品(该产品)为本公司化妆品品牌KOSHIN旗下以KX-826为主 要成分的产品之一。本公司谨此澄清，尽管销售代理协议为进一步推动本公司化妆品商业化提供了有利 机会，但与本集团的上市业务(即本公司核心产品KX-826及GT20029及其他管线产品的开发及商业化) (上市业务)相比，该化妆品销售业务目前规模较小，属辅助性质。谨此说明，该公告所披露的人民币1 亿元销售目标是按累计基准计量的长期目标，而非预期于短期内达致的销售额指标。 人力资源方面，截至本公告日期，在本公司现有的121名雇员中，有69名雇员专门负责药物研发、药物 供应及本地GMP生产，另有24名雇员目前专门负责化妆品销售及本公司候选药物的市场推广及销售准 备。资金方面，根据本公司的管理账目，研发开支预期占本公司截至2025年12月31日止年度开支总额的 50%以上，主要是由于将资金用于KX-826在中国治疗雄激素性脱发(男性)的II期及III期临床研究;及 GT20029在中国治疗痤疮的II期临床研究。 董事已审阅本集团自2025年12月31日起不少于12个月期间的现金流量预测。经考虑(其中包括)本公司 ...

人力资源方面，截至本公告日期，在本公司现有的121名雇员中，有69名雇员专门负责药物研发、药物 供应及本地GMP生产，另有24名雇员目前专门负责化妆品销售及本公司候选药物的市场推广及销售准 备。资金方面，根据本公司的管理账目，研发开支预期占本公司截至2025年12月31日止年度开支总额的 50%以上，主要是由于将资金用于 KX-826在中国治疗雄激素性脱发(男性)的II期及III期临床研究;及 GT20029在中国治疗痤疮的II期临床研究。 董事会确认：本公司将利用其化妆品业务(包括销售该产品)的现金流量为其医疗/生物应用及开发提供资 金;及本公司将继续恪守其上市业务的既定方针。 董事已审阅本集团自2025年12月31日起不少于12个月期间的现金流量预测。经考虑(其中包括)本公司正 积极与数家银行磋商银行融资，而该银行融资预期将于2026年第一季度授出及提取;及本公司正积极寻 求股本融资，并已与若干潜在投资者磋商认购本公司新股份，董事认为本公司的财务资源及流动资金充 足，可为其营运、研发及其核心产品的商业化准备提供资金。 智通财经APP讯，开拓药业-B(09939)发布公告，防脱泡沫剂产品(该产品)为本公司化 ...

Company Developments - Baiyunshan announced that its subsidiary Tianxin Pharmaceutical and Baiyunshan Pharmaceutical Factory plan to participate in the national drug procurement for 24 products, with projected sales revenue of 798 million yuan in 2024, accounting for 1.06% of the company's revenue, and 550 million yuan in the first three quarters of 2025, accounting for 0.89% [2] - Baiyunshan's subsidiaries, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., received production license changes from the Guangdong Provincial Drug Administration to enhance production capacity and efficiency, although no significant financial impact is expected in the current period [3] Product Development - Baiyunshan's subsidiary Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd. has successfully passed the consistency evaluation of quality and efficacy for its Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [4] Financial Movements - Morgan Stanley increased its stake in Baiyunshan H-shares by 360,600 shares at approximately 18.85 HKD per share on January 30, raising its ownership to 9.12% [5] - The company reported a year-on-year increase in revenue and net profit in its Q3 2025 report, emphasizing its ongoing dividend policy and capital operations [5]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has participated in the national organized procurement for drugs whose agreements have expired, with several of its products expected to be selected in this procurement process [1] Group 1: Procurement Details - The procurement involves products from the first to the eighth batch of national organized procurement agreements that have expired, with the purchasing volume based on the demand reported by medical institutions [1] - The procurement cycle will last until December 31, 2028, starting from the actual implementation date of the selected results [1] Group 2: Financial Impact - A total of 12 products from the company are expected to be selected, with projected sales revenue of 176.18 million yuan for 2024, accounting for 12.47% of the company's total revenue for that year [1] - For the period of January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 3: Market Implications - Medical institutions will prioritize the use of the selected drugs from this procurement, ensuring the completion of the agreed purchasing volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and enhance the company's brand influence in the domestic market [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 開 拓 藥 業 有 限 公 司 * KINTOR PHARMACEUTICAL LIMITED （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9939） 有關自願公告的補充公告 茲提述日期為2026年1月21日的自願公告（「該公告」）。除文義另有所指外，本 公告所用詞彙與該公告所界定者具有相同涵義。 董事會謹此提供進一步資料說明，防脫泡沫劑產品（「該產品」）為本公司化妝 品品牌KOSHINÉ旗下以KX-826為主要成分的產品之一。本公司謹此澄清，儘 管銷售代理協議為進一步推動本公司化妝品商業化提供了有利機會，但與本 集團的上市業務（即本公司核心產品KX-826及GT20029及其他管線產品的開發 及商業化）（「上市業務」）相比，該化妝品銷售業務目前規模較小，屬輔助性質。 謹此說明，該公告所披露的人民幣100百萬元銷售目標是按累計基準計量的長 期目標，而非預期於短期內達致 ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has participated in the national organized procurement for drugs whose agreements have expired, with several of its products expected to be selected in this procurement process [1] Group 1: Procurement Details - The procurement involves products from the first to the eighth batch of national organized procurement agreements that have expired, with the purchasing volume based on the demand reported by medical institutions [1] - The procurement cycle will last until December 31, 2028, starting from the actual implementation date of the selected results [1] Group 2: Financial Impact - The company expects to achieve sales revenue of 176.18 million yuan from the selected products in 2024, accounting for 12.47% of the company's total revenue for that year [1] - For the period from January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 3: Market Implications - Medical institutions will prioritize the use of the selected drugs from this procurement, ensuring the completion of the agreed purchasing volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and enhance the company's brand influence in the domestic market [1]

Core Viewpoint - The company is actively progressing with the registration review of its innovative drug, Sodium Dehydroacetic Acid, and will disclose significant updates in accordance with regulatory requirements [1] Group 1: Drug Development and Approval - The registration review of Sodium Dehydroacetic Acid is proceeding in an orderly manner, with the specific progress dependent on the National Medical Products Administration (NMPA) [1] - The company maintains good communication with multiple clinical institutions involved in the research, establishing a solid professional foundation for future commercialization [1] - The company is open to collaborating with experienced and capable large teams for the promotion of this product [1] Group 2: Business Strategy and Operations - The company is actively expanding its overseas sales through localized strategies and is increasing efforts in Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) businesses [1] - The company is implementing cost reduction and efficiency enhancement measures to address industry competition and operational pressures [1] - The management is committed to protecting shareholder interests and ensuring sustainable operations, with plans to dynamically adjust development strategies based on industry trends and actual business conditions [1]

Core Viewpoint - Warner Pharmaceuticals announced participation in the national organized procurement for drugs, with 12 products expected to be selected, including Montmorillonite Powder and Mycophenolate Mofetil Capsules [1] Group 1: Procurement Details - The procurement cycle will last from the actual execution date of the selection results until December 31, 2028 [1] - The projected sales revenue for selected products in 2024 is 176.18 million yuan, accounting for 12.47% of the annual revenue [1] - For the period from January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the revenue during the same period [1] Group 2: Future Implications - If procurement contracts are signed and executed, it will expand the sales scale of the products [1] - There is uncertainty regarding the signing of procurement contracts and the execution of market sales [1]

过去的2025年，既非生物医药的寒冬，也未被产业泡沫裹挟；更不是只谈买卖、单纯依靠管线出海兑现以求生存的一年，而是生物医药产业逐步回归理性价 值与长期主义的一年。 对我们而言，AI之于生物医药，远不止是降本增效的工具，更是在源头创新上打开了全新的空间。通过AI，我们能够探索以往人类经验难以触达的新靶 点，设计结构更为精妙的分子。AI正在加速打破新药研发"双十定律"（十年、十亿美金）的束缚，让那些曾被认为不可成药的靶点成为可能。 展望2026年，对英矽智能来说，更重要的是持续拓展更广阔的边界，包括生命科学周边领域与新分子实体的探索。例如，我们近期宣布在宜兴建立AI驱动 的自动化多肽筛选实验平台。同时，BD仍将是我们的主旋律，我们期待更多管线在不同阶段与合作伙伴达成研发合作。此外，我们近期提出MMAI Gym框 架，期待赋能LLM在垂直领域的专精能力训练。 （经济观察报 记者 张铃） 2025年对英矽智能而言同样收获颇丰。我们实现了靶向KIF18A的肿瘤项目、靶向PHD1/2的肾性贫血项目两条管线的全部或部分对外授权；推动了与礼来、 施维雅、海正药业、复星医药等跨国或大型制药公司的研发合作；并在6个临床项目与5个 ...

Core Viewpoint - Meihua announced that its wholly-owned subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., participated in the national centralized procurement for drugs whose agreements have expired, with ten products expected to be selected for this procurement [1] Group 1: Procurement Participation - The selected products include Perindopril tert-butylamine tablets, Clopidogrel hydrogen sulfate tablets, and Empagliflozin tablets among others [1] - The procurement is part of the continuation of the national centralized procurement for drugs from batches 1-8, with results expected to be implemented by the end of March 2026 [1] Group 2: Financial Impact - The total sales for the ten selected products are projected to be 71.75 million yuan for the first three quarters of 2025, accounting for 6.4% of the company's total revenue during the same period [1] - The number of selected products represents 40% of the total products in the formulation segment of the company [1] Group 3: Procurement Cycle - The procurement cycle for the selected drugs will run from the actual execution date of the selection results until December 31, 2028 [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle and ensure the completion of the agreed procurement volume [1]